Theracurmin®  ||| S:0 E:13 ||| NNP
efficiently  ||| S:13 E:25 ||| RB
inhibits  ||| S:25 E:34 ||| VB
the  ||| S:34 E:38 ||| DT
growth  ||| S:38 E:45 ||| NN
of  ||| S:45 E:48 ||| IN
human  ||| S:48 E:54 ||| JJ
prostate  ||| S:54 E:63 ||| NN
and  ||| S:63 E:67 ||| CC
bladder  ||| S:67 E:75 ||| JJ
cancer  ||| S:75 E:82 ||| NN
cells  ||| S:82 E:88 ||| NNS
via  ||| S:88 E:92 ||| IN
induction  ||| S:92 E:102 ||| NN
of  ||| S:102 E:105 ||| IN
apoptotic  ||| S:105 E:115 ||| JJ
cell  ||| S:115 E:120 ||| NN
death  ||| S:120 E:126 ||| NN
and  ||| S:126 E:130 ||| CC
cell  ||| S:130 E:135 ||| NN
cycle  ||| S:135 E:141 ||| NN
arrest  ||| S:141 E:148 ||| NN
In  ||| S:148 E:151 ||| IN
the  ||| S:151 E:155 ||| DT
present  ||| S:155 E:163 ||| JJ
study ||| S:163 E:168 ||| NN
,  ||| S:168 E:170 ||| ,
we  ||| S:170 E:173 ||| PRP
aimed  ||| S:173 E:179 ||| VBD
to  ||| S:179 E:182 ||| TO
investigate  ||| S:182 E:194 ||| VB
the  ||| S:194 E:198 ||| DT
anticancer  ||| S:198 E:209 ||| JJ
properties  ||| S:209 E:220 ||| NNS
of  ||| S:220 E:223 ||| IN
Theracurmin® ||| S:223 E:235 ||| NNP
,  ||| S:235 E:237 ||| ,
a  ||| S:237 E:239 ||| DT
novel  ||| S:239 E:245 ||| NN
form  ||| S:245 E:250 ||| NN
of  ||| S:250 E:253 ||| IN
the  ||| S:253 E:257 ||| DT
yellow  ||| S:257 E:264 ||| JJ
curry  ||| S:264 E:270 ||| JJ
pigment  ||| S:270 E:278 ||| NN
curcumin ||| S:278 E:286 ||| NN
,  ||| S:286 E:288 ||| ,
as  ||| S:288 E:291 ||| RB
well  ||| S:291 E:296 ||| RB
as  ||| S:296 E:299 ||| RB
explore  ||| S:299 E:307 ||| VB
the  ||| S:307 E:311 ||| DT
molecular  ||| S:311 E:321 ||| JJ
mechanisms  ||| S:321 E:332 ||| NNS
of  ||| S:332 E:335 ||| IN
the  ||| S:335 E:339 ||| DT
potential  ||| S:339 E:349 ||| JJ
anticancer  ||| S:349 E:360 ||| JJ
effects  ||| S:360 E:368 ||| NNS
of  ||| S:368 E:371 ||| IN
Theracurmin®  ||| S:371 E:384 ||| CD
on  ||| S:384 E:387 ||| IN
human  ||| S:387 E:393 ||| JJ
prostate  ||| S:393 E:402 ||| JJ
cancer  ||| S:402 E:409 ||| NN
and  ||| S:409 E:413 ||| CC
bladder  ||| S:413 E:421 ||| JJ
cancer  ||| S:421 E:428 ||| NN
cells  ||| S:428 E:434 ||| NNS
in vitro ||| S:434 E:442 ||| VBP
.  ||| S:442 E:444 ||| .
The  ||| S:444 E:448 ||| DT
proliferation  ||| S:448 E:462 ||| NN
of  ||| S:462 E:465 ||| IN
cancer  ||| S:465 E:472 ||| NN
cells  ||| S:472 E:478 ||| NNS
was  ||| S:478 E:482 ||| VBD
examined  ||| S:482 E:491 ||| VBN
by  ||| S:491 E:494 ||| IN
using  ||| S:494 E:500 ||| VBG
the  ||| S:500 E:504 ||| DT
Cell  ||| S:504 E:509 ||| NNP
Counting  ||| S:509 E:518 ||| NNP
Kit-8 ||| S:518 E:523 ||| NNP
.  ||| S:523 E:525 ||| .
The  ||| S:525 E:529 ||| DT
clonogenic  ||| S:529 E:540 ||| JJ
growth  ||| S:540 E:547 ||| NN
potential  ||| S:547 E:557 ||| NN
was  ||| S:557 E:561 ||| VBD
determined  ||| S:561 E:572 ||| VBN
by  ||| S:572 E:575 ||| IN
clonogenic  ||| S:575 E:586 ||| JJ
assay ||| S:586 E:591 ||| NN
.  ||| S:591 E:593 ||| .
Cell  ||| S:593 E:598 ||| NN
cycle  ||| S:598 E:604 ||| NN
distribution  ||| S:604 E:617 ||| NN
was  ||| S:617 E:621 ||| VBD
evaluated  ||| S:621 E:631 ||| VBN
by  ||| S:631 E:634 ||| IN
flow  ||| S:634 E:639 ||| NN
cytometry  ||| S:639 E:649 ||| VBZ
using  ||| S:649 E:655 ||| VBG
propidium  ||| S:655 E:665 ||| JJ
iodide  ||| S:665 E:672 ||| JJ
staining ||| S:672 E:680 ||| NN
.  ||| S:680 E:682 ||| .
Western  ||| S:682 E:690 ||| JJ
blot  ||| S:690 E:695 ||| JJ
analysis  ||| S:695 E:704 ||| NN
was  ||| S:704 E:708 ||| VBD
applied  ||| S:708 E:716 ||| VBN
to  ||| S:716 E:719 ||| TO
explore  ||| S:719 E:727 ||| VB
the  ||| S:727 E:731 ||| DT
expression  ||| S:731 E:742 ||| NN
patterns  ||| S:742 E:751 ||| NNS
of  ||| S:751 E:754 ||| IN
molecules  ||| S:754 E:764 ||| NNS
associated  ||| S:764 E:775 ||| VBN
with  ||| S:775 E:780 ||| IN
apoptotic  ||| S:780 E:790 ||| JJ
cell  ||| S:790 E:795 ||| NN
death  ||| S:795 E:801 ||| NN
and  ||| S:801 E:805 ||| CC
cell  ||| S:805 E:810 ||| NN
cycle  ||| S:810 E:816 ||| NN
checkpoint ||| S:816 E:826 ||| NN
.  ||| S:826 E:828 ||| .
We  ||| S:828 E:831 ||| PRP
noted  ||| S:831 E:837 ||| VBD
that  ||| S:837 E:842 ||| IN
Theracurmin®  ||| S:842 E:855 ||| NNP
and  ||| S:855 E:859 ||| CC
curcumin  ||| S:859 E:868 ||| JJ
exhibited  ||| S:868 E:878 ||| JJ
similar  ||| S:878 E:886 ||| JJ
anticancer  ||| S:886 E:897 ||| JJ
effects  ||| S:897 E:905 ||| NNS
in  ||| S:905 E:908 ||| IN
both  ||| S:908 E:913 ||| DT
androgen-dependent  ||| S:913 E:932 ||| JJ
and  ||| S:932 E:936 ||| CC
-independent  ||| S:936 E:949 ||| JJ
human  ||| S:949 E:955 ||| JJ
prostate  ||| S:955 E:964 ||| JJ
cancer  ||| S:964 E:971 ||| NN
cells  ||| S:971 E:977 ||| NNS
in  ||| S:977 E:980 ||| IN
a  ||| S:980 E:982 ||| DT
dose-  ||| S:982 E:988 ||| JJ
and  ||| S:988 E:992 ||| CC
time-dependent  ||| S:992 E:1007 ||| JJ
manner ||| S:1007 E:1013 ||| NN
.  ||| S:1013 E:1015 ||| .
These  ||| S:1015 E:1021 ||| DT
agents  ||| S:1021 E:1028 ||| NNS
reduced  ||| S:1028 E:1036 ||| VBN
cell  ||| S:1036 E:1041 ||| NN
viability  ||| S:1041 E:1051 ||| NN
and  ||| S:1051 E:1055 ||| CC
clonogenic  ||| S:1055 E:1066 ||| JJ
growth  ||| S:1066 E:1073 ||| NN
potential  ||| S:1073 E:1083 ||| NN
by  ||| S:1083 E:1086 ||| IN
inducing  ||| S:1086 E:1095 ||| VBG
apoptosis  ||| S:1095 E:1105 ||| NNS
and  ||| S:1105 E:1109 ||| CC
cell  ||| S:1109 E:1114 ||| NN
cycle  ||| S:1114 E:1120 ||| NN
disturbance  ||| S:1120 E:1132 ||| NN
in  ||| S:1132 E:1135 ||| IN
human  ||| S:1135 E:1141 ||| JJ
prostate  ||| S:1141 E:1150 ||| JJ
cancer  ||| S:1150 E:1157 ||| NN
cells ||| S:1157 E:1162 ||| NNS
.  ||| S:1162 E:1164 ||| .
Theracurmin®  ||| S:1164 E:1177 ||| NNP
and  ||| S:1177 E:1181 ||| CC
curcumin  ||| S:1181 E:1190 ||| VBP
also  ||| S:1190 E:1195 ||| RB
exerted  ||| S:1195 E:1203 ||| VBN
marked  ||| S:1203 E:1210 ||| VBN
anticancer  ||| S:1210 E:1221 ||| JJ
effects  ||| S:1221 E:1229 ||| NNS
on  ||| S:1229 E:1232 ||| IN
human  ||| S:1232 E:1238 ||| JJ
bladder  ||| S:1238 E:1246 ||| NN
cancer  ||| S:1246 E:1253 ||| NN
cells ||| S:1253 E:1258 ||| NNS
,  ||| S:1258 E:1260 ||| ,
even  ||| S:1260 E:1265 ||| RB
in  ||| S:1265 E:1268 ||| IN
cisplatin-resistant  ||| S:1268 E:1288 ||| JJ
T24R2  ||| S:1288 E:1294 ||| CD
cells ||| S:1294 E:1299 ||| NNS
,  ||| S:1299 E:1301 ||| ,
in  ||| S:1301 E:1304 ||| IN
a  ||| S:1304 E:1306 ||| DT
dose-  ||| S:1306 E:1312 ||| JJ
and  ||| S:1312 E:1316 ||| CC
time-dependent  ||| S:1316 E:1331 ||| JJ
manner ||| S:1331 E:1337 ||| NN
.  ||| S:1337 E:1339 ||| .
Moreover ||| S:1339 E:1347 ||| RB
,  ||| S:1347 E:1349 ||| ,
Theracurmin®  ||| S:1349 E:1362 ||| NNP
and  ||| S:1362 E:1366 ||| CC
curcumin  ||| S:1366 E:1375 ||| JJ
treatment  ||| S:1375 E:1385 ||| NN
decreased  ||| S:1385 E:1395 ||| VBD
cell  ||| S:1395 E:1400 ||| NN
viability  ||| S:1400 E:1410 ||| NN
and  ||| S:1410 E:1414 ||| CC
clonogenicity  ||| S:1414 E:1428 ||| NN
via  ||| S:1428 E:1432 ||| IN
induction  ||| S:1432 E:1442 ||| NN
of  ||| S:1442 E:1445 ||| IN
apoptotic  ||| S:1445 E:1455 ||| JJ
cell  ||| S:1455 E:1460 ||| NN
death  ||| S:1460 E:1466 ||| NN
and  ||| S:1466 E:1470 ||| CC
cell  ||| S:1470 E:1475 ||| NN
cycle  ||| S:1475 E:1481 ||| NN
dysregulation  ||| S:1481 E:1495 ||| NN
in  ||| S:1495 E:1498 ||| IN
human  ||| S:1498 E:1504 ||| JJ
bladder  ||| S:1504 E:1512 ||| NN
cancer  ||| S:1512 E:1519 ||| NN
cells ||| S:1519 E:1524 ||| NNS
.  ||| S:1524 E:1526 ||| .
In  ||| S:1526 E:1529 ||| IN
conclusion ||| S:1529 E:1539 ||| NN
,  ||| S:1539 E:1541 ||| ,
our  ||| S:1541 E:1545 ||| PRP$
study  ||| S:1545 E:1551 ||| NN
suggests  ||| S:1551 E:1560 ||| VBZ
that  ||| S:1560 E:1565 ||| IN
Theracurmin®  ||| S:1565 E:1578 ||| NNP
has  ||| S:1578 E:1582 ||| VBZ
potential  ||| S:1582 E:1592 ||| JJ
as  ||| S:1592 E:1595 ||| IN
an  ||| S:1595 E:1598 ||| DT
anticancer  ||| S:1598 E:1609 ||| JJ
agent  ||| S:1609 E:1615 ||| NN
in  ||| S:1615 E:1618 ||| IN
complementary  ||| S:1618 E:1632 ||| JJ
and  ||| S:1632 E:1636 ||| CC
alternative  ||| S:1636 E:1648 ||| JJ
medicine  ||| S:1648 E:1657 ||| NN
for  ||| S:1657 E:1661 ||| IN
these  ||| S:1661 E:1667 ||| DT
urological  ||| S:1667 E:1678 ||| JJ
cancers ||| S:1678 E:1685 ||| NNS
.  ||| S:1685 E:1687 ||| .
